BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 25635756)

  • 1. Allogeneic haematopoietic stem cell transplantation for primary myelofibrosis and myelofibrosis evolved from other myeloproliferative neoplasms.
    Tamari R; Castro-Malaspina H
    Curr Opin Hematol; 2015 Mar; 22(2):184-90. PubMed ID: 25635756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Barosi G; Bacigalupo A
    Curr Opin Hematol; 2006 Mar; 13(2):74-8. PubMed ID: 16456372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.
    Alchalby H; Kröger N
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S36-41. PubMed ID: 25486953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.
    Kekre N; Ho VT
    Am J Hematol; 2016 Jan; 91(1):123-30. PubMed ID: 26453238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation.
    Alchalby H; Zabelina T; Stübig T; van Biezen A; Bornhäuser M; Di Bartolomeo P; Beelen D; Cahn JY; Dreger P; Schroyens W; de Witte T; Olavarria E; Kröger N;
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):279-81. PubMed ID: 24201159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis.
    Lissandre S; Bay JO; Cahn JY; Porcher R; Cacheux V; Cabrespine A; Cornillon J; Cassinat B; Peffault de Latour R; Socie G; Robin M
    Bone Marrow Transplant; 2011 Apr; 46(4):557-61. PubMed ID: 21042309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversies and dilemmas in allogeneic transplantation for myelofibrosis.
    Shanavas M; Gupta V
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):165-74. PubMed ID: 25189727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Ditschkowski M; Elmaagacli AH; Trenschel R; Gromke T; Steckel NK; Koldehoff M; Beelen DW
    Haematologica; 2012 Oct; 97(10):1574-81. PubMed ID: 22491742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic stem-cell transplantation for myelofibrosis.
    Lavi N; Rowe JM; Zuckerman T
    Curr Opin Hematol; 2017 Nov; 24(6):475-480. PubMed ID: 28832353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
    Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits?
    Babushok D; Hexner E
    Curr Opin Hematol; 2014 Mar; 21(2):114-22. PubMed ID: 24378706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choosing between stem cell therapy and drugs in myelofibrosis.
    Kröger N; Mesa RA
    Leukemia; 2008 Mar; 22(3):474-86. PubMed ID: 18185525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis.
    El Fakih R; Popat U
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S34-42. PubMed ID: 26297276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.
    Ballinger TJ; Savani BN; Gupta V; Kroger N; Mohty M
    Eur J Haematol; 2015 Feb; 94(2):115-9. PubMed ID: 25256963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years.
    Daghia G; Zabelina T; Zeck G; von Pein UM; Christopeit M; Wolschke C; Ayuk F; Kröger N
    Eur J Haematol; 2019 Oct; 103(4):370-378. PubMed ID: 31306511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management.
    Ali H; Bacigalupo A
    Am J Hematol; 2024 May; 99(5):938-945. PubMed ID: 38450790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
    Robin M; Tabrizi R; Mohty M; Furst S; Michallet M; Bay JO; Cahn JY; De Coninck E; Dhedin N; Bernard M; Rio B; Buzyn A; Huynh A; Bilger K; Bordigoni P; Contentin N; Porcher R; Socié G; Milpied N
    Br J Haematol; 2011 Feb; 152(3):331-9. PubMed ID: 21133885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review.
    Farhadfar N; Cerquozzi S; Patnaik M; Tefferi A
    J Oncol Pract; 2016 Jul; 12(7):611-21. PubMed ID: 27407157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT.
    McLornan DP; Szydlo R; Robin M; van Biezen A; Koster L; Blok HJP; Van Lint MT; Finke J; Vitek A; Carlson K; Griskevicius L; Holler E; Itälä-Remes M; Schaap M; Socié G; Bay JO; Beguin Y; Bruno B; Cornelissen JJ; Gedde-Dahl T; Ljungman P; Rubio MT; Yakoub-Agha I; Klyuchnikov E; Olavarria E; Chalandon Y; Kröger N
    Br J Haematol; 2018 Aug; 182(3):418-422. PubMed ID: 29808926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.